Searchable abstracts of presentations at key conferences in endocrinology

ea0078OC8.1 | Oral Communications 8 | BSPED2021

Cystic fibrosis related diabetes (CFRD): could Cystic Fibrosis Transport Receptor (CFTR) modulators be the answer?

Park Julie , Walsh Anna , Kerr Sue , Woodland Clare , Southward Suzanne , Deakin Mark , Thursfield Rebecca , Senniappan Senthil

Background: Cystic Fibrosis related diabetes affects 40-50% of adults with cystic fibrosis (CF). This can significantly affect pulmonary function and life expectancy. Kaftrio (Ivakaftor, tezacaftor and elexacaftor) has recently been licensed for use in CF. Previous data highlight that glucose regulation may be altered on commencing this treatment.Methods: Eight children and young people (CYP), aged 14 (12-15) years, who were diagnosed with CFRD aged 12.8...

ea0066oc7.4 | Oral Communications 7 | BSPED2019

Monitoring lipid profiles in children and young people with type 1 diabetes mellitus: what should we do with these results?

Park Julie , Bowker Tabitha , Ghatak Atrayee , Mehta Fulya , Deakin Mark , Paul Princy

Introduction: Evidence is currently limited regarding the management of abnormal lipid profiles in children and young people (CYP) with Type 1 Diabetes Mellitus (T1DM). ISPAD recommend monitoring every five years and statin use to maintain LDL cholesterol <3.4 mmol/L1. Guidance is specific to LDL. NICE guidelines do no recommend routine screening for CYP with T1DM.Methodology: We reviewed all lipid profiles (including cholesterol, triglyce...